| 1 |
Biolato M, Vitale F, Marrone G, Miele L, Grieco A. Two elective invasive procedures after a single avatrombopag treatment in a patient with liver cirrhosis and severe thrombocytopenia. Gastroenterol Rep (Oxf) 2022;10:goac059. [PMID: 36340807 DOI: 10.1093/gastro/goac059] [Reference Citation Analysis]
|
| 2 |
Maevskaya MV, Zharkova MS, Ivashkin VT, Bessonova EN, Geyvandova NI, Kitsenko EA, Korochanskaya NV, Kurkina IA, Melikyan AL, Morozov VG, Khoronko YV. Diagnosis of disorders in the coagulation system, assessment of the risk of hemorrhagic complications in severe cirrhosis/liver diseases according to global screening tests of the hemostasis system and principles for their correction: guidelines. Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-15-70-82] [Reference Citation Analysis]
|
| 3 |
Orme ME, Bentley R, Marcella S, Peck-Radosavljevic M, Perard R, Wedemeyer H, Yoshiji H, Agarwal K, Dusheiko G. Systematic Review with Meta-Analysis: Efficacy and Safety of Lusutrombopag for Severe Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures. Adv Ther 2022. [PMID: 35836089 DOI: 10.1007/s12325-022-02235-w] [Reference Citation Analysis]
|
| 4 |
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J Hepatol 2022;76:1151-84. [PMID: 35300861 DOI: 10.1016/j.jhep.2021.09.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 37.0] [Reference Citation Analysis]
|
| 5 |
Zhang G. Platelet-Related Molecular Subtype to Predict Prognosis in Hepatocellular Carcinoma. JHC 2022;Volume 9:423-36. [DOI: 10.2147/jhc.s363200] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 6 |
Dakua SP, Nayak A. A review on treatments of hepatocellular carcinoma—role of radio wave ablation and possible improvements. Egypt Liver Journal 2022;12. [DOI: 10.1186/s43066-022-00191-2] [Reference Citation Analysis]
|
| 7 |
Yoshiji H, Ueno Y, Kurosaki M, Torimura T, Hatano E, Yatsuhashi H, Yamakado K. Treatment algorithm for thrombocytopenia in patients with chronic liver disease undergoing planned invasive procedures. Hepatol Res 2021;51:1181-95. [PMID: 34555262 DOI: 10.1111/hepr.13715] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Santos-Veloso MAO, Souza GLO, Sá AF. Prophylactic blood transfusion prior to elective invasive procedures. Rev Assoc Med Bras (1992) 2021;67:1353-60. [PMID: 34816934 DOI: 10.1590/1806-9282.20210468] [Reference Citation Analysis]
|
| 9 |
Flisiak R, Antonov K, Drastich P, Jarcuska P, Maevskaya M, Makara M, Puljiz Ž, Štabuc B, Trifan A. Practice Guidelines of the Central European Hepatologic Collaboration (CEHC) on the Use of Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease Undergoing Invasive Procedures. J Clin Med 2021;10. [PMID: 34830701 DOI: 10.3390/jcm10225419] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 10 |
Alvaro D, Caporaso N, Giannini EG, Iacobellis A, Morelli M, Toniutto P, Violi F; PReBRiC (Procedure-Related Bleeding Risk in Cirrhosis) group. Procedure-related bleeding risk in patients with cirrhosis and severe thrombocytopenia. Eur J Clin Invest 2021;51:e13508. [PMID: 33539542 DOI: 10.1111/eci.13508] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
|
